$25.18
+0.61 (+2.48%)
Last updated: Apr 16, 2026 00:43
Fundamentals Overview
Ultragenyx Pharmaceutical Inc. is in the middle of its 52-week range with moderate valuation, trending upward today.
Valuation moderate
Risk (Beta)
0.25 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Sentiment improving (1 upgrade) · 3M vs Healthcare sector: +9.4%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: C+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 9, Neutral: 6, Outperform: 2, Overweight: 13.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-504.49; current price is $25.18. That’s a -2103.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | N/A |
| P/S (TTM) | 3.62 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.48 |
| Quick Ratio (TTM) | 2.34 |
| Cash Ratio (TTM) | 1.13 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -85.54% |
| Gross margin (TTM) | 83.85% |
| Operating margin (TTM) | -79.63% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for RARE.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-10-22 |
| TD Cowen | maintain | Buy | Buy | 2024-10-21 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-10-01 |
| RBC Capital | maintain | Outperform | Outperform | 2024-09-26 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-09-20 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-09-16 |
| Barclays | maintain | Overweight | Overweight | 2024-08-05 |
| Wells Fargo | maintain | Overweight | Overweight | 2024-08-02 |
| Wedbush | maintain | Neutral | Neutral | 2024-08-02 |
| Goldman Sachs | maintain | Buy | Buy | 2024-08-02 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-08-02 |
| Canaccord Genuity | maintain | Buy | Buy | 2024-07-23 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-07-22 |
| Wedbush | maintain | Neutral | Neutral | 2024-07-18 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-06-12 |
| Goldman Sachs | upgrade | Neutral | Buy | 2024-06-06 |
| B of A Securities | maintain | Buy | Buy | 2024-05-31 |
| Baird | maintain | Outperform | Outperform | 2024-05-31 |
| Wedbush | maintain | Neutral | Neutral | 2024-05-31 |
| Stifel | maintain | Buy | Buy | 2024-05-31 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-05-31 |
| Canaccord Genuity | maintain | Buy | Buy | 2024-05-31 |
| Canaccord Genuity | maintain | Buy | Buy | 2024-05-06 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-05-03 |
| Wedbush | maintain | Neutral | Neutral | 2024-05-03 |
| TD Cowen | maintain | Buy | Buy | 2024-04-24 |
| Wedbush | maintain | Neutral | Neutral | 2024-04-17 |
| Wedbush | maintain | Neutral | Neutral | 2024-04-16 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2024-04-05 |
| JP Morgan | maintain | Overweight | Overweight | 2024-03-18 |